L. Abad

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

Helen X. Chen, G. Abou-Alfa, L. Saltz, 2014, Journal of hepatology.

Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available.

L. Benjamin, R. Martell, E. Chiorean, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402).

J. Sparano, H. Youssoufian, K. Miller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.